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EVIDENCE BASED MEDICINE
CLEAR: The Intraventricular Haemorrhage Thrombolysis Trial
Anjum Akhtar, Ayeesha Kamran Kamal
Availability of a well-equipped stroke unit, intravenous
thrombolysis and expert stroke teams has dramatically
improved stroke outcomes for acute ischaemic stroke.
Stroke from intracerebral haemorrhage (ICH), however,
still carries a high mortality rate. ICH related to high blood
pressure accounts for 10 to 20% of the stroke worldwide
with a mortality of 50 to 80% in those with intraventricular
extension due to associated obstructive hydrocephalous
and perilesional oedema. Any strategy to overcome this
obstacle will help to minimise the future morbidity.

What is the study under consideration?
CLEAR is a phase III clinical trial testing low dose
thrombolytic therapy in patients presenting with ICH with
intraventricular extension within 4 hours. The sample
constituted 48 patients enrolled from 14 centres. Adults
aged 18 to 75 years with supratentorial ICH of less than 30
ml with massive IV extension and an external ventricular
drain already in place for treatment of obstructive
hydrocephalous were selected for this trial.

What was the study design?
The patients were randomised to treatment with 3mg
intraventricular rtPA through external ventricular drain or
placebo (3ml of normal saline). Medicine or placebo were
given 12 hourly and continued till they found the
evidence of resolution of clot which was 7.5 days for rtPA
and 12 days for placebo. Clot resolution was measured
with daily CT scan of the brain.
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What were the results?
Rate of clot resolution was significantly higher in the rtPA
treated group which was 18%/day versus 8%/day in the
placebo treated patients. This was statistically significant.

Why is this study important?
We have had very little option in improving the outcome
of the patients with ICH up till now. Intraventricular
thrombolysis may prove to be beneficial in ICH. Though
several other small clinical trials have also shown the
significant benefit of low dose thrombolysis using
intraventricular catheter, but further data is needed to
support this evidence.

What this means for Pakistan?
We should be on the alert for future data on this
therapeutic option, since our outcomes may be even
better than reported given the young, frequent ICH with
intraventricular extension in our region.

Acknowledgement and Disclosure
Statement
The International Cerebrovascular Translational Clinical
Research and Training Program (ICT_CRT) at the Aga Khan
University is supported by funds from the Award Number
D43TW008660 from the Fogarty International Center and
the National Institute of Neurologic Disorders and Stroke.
The content is solely the responsibility of the authors and
does not necessarily represent the official views of the
Fogarty International Center or the National Institutes of
Health.

Recommended Reading
1.

Naff N, Williams MA, Keyl PM, Tuhrim S, Bullock MR, Mayer SA, et al.
Low-dose recombinant tissue-type plasminogen activator
enhances clot resolution in brain haemorrhage: the intraventricular
haemorrhage thrombolysis trial. Stroke 2011; 42: 3009-16.

J Pak Med Assoc

